X4 Pharmaceuticals Inc.

0.19
-0.00 (-0.42%)
At close: Apr 21, 2025, 3:59 PM
0.19
0.29%
Pre-market: Apr 22, 2025, 04:03 AM EDT

X4 Pharmaceuticals Statistics

Share Statistics

X4 Pharmaceuticals has 173.66M shares outstanding. The number of shares has increased by 3.41% in one year.

Shares Outstanding 173.66M
Shares Change (YoY) 3.41%
Shares Change (QoQ) 1.83%
Owned by Institutions (%) 49.7%
Shares Floating 115.02M
Failed to Deliver (FTD) Shares 397
FTD / Avg. Volume 0.01%

Short Selling Information

The latest short interest is 8.08M, so 4.65% of the outstanding shares have been sold short.

Short Interest 8.08M
Short % of Shares Out 4.65%
Short % of Float 4.71%
Short Ratio (days to cover) 4.37

Valuation Ratios

The PE ratio is -3.94 and the forward PE ratio is -0.53. X4 Pharmaceuticals's PEG ratio is 0.06.

PE Ratio -3.94
Forward PE -0.53
PS Ratio 57.68
Forward PS 0.1
PB Ratio 6.66
P/FCF Ratio -1.12
PEG Ratio 0.06
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for X4 Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.12.

Current Ratio 3.41
Quick Ratio 3.33
Debt / Equity 0.12
Debt / EBITDA -0.1
Debt / FCF -0.02
Interest Coverage -4.15

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $17.88K
Profits Per Employee $-261.89K
Employee Count 143
Asset Turnover 0.02
Inventory Turnover 0.28

Taxes

Income Tax 310K
Effective Tax Rate -0.83%

Stock Price Statistics

The stock price has increased by -86.03% in the last 52 weeks. The beta is 0.58, so X4 Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.58
52-Week Price Change -86.03%
50-Day Moving Average 0.33
200-Day Moving Average 0.54
Relative Strength Index (RSI) 28.73
Average Volume (20 Days) 3.35M

Income Statement

In the last 12 months, X4 Pharmaceuticals had revenue of 2.56M and earned -37.45M in profits. Earnings per share was -0.19.

Revenue 2.56M
Gross Profit 1.76M
Operating Income -36.4M
Net Income -37.45M
EBITDA -27.58M
EBIT -28.37M
Earnings Per Share (EPS) -0.19
Full Income Statement

Balance Sheet

The company has 55.7M in cash and 2.66M in debt, giving a net cash position of 53.04M.

Cash & Cash Equivalents 55.7M
Total Debt 2.66M
Net Cash 53.04M
Retained Earnings -515.36M
Total Assets 146.45M
Working Capital 79.3M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -130.9M and capital expenditures -326K, giving a free cash flow of -131.23M.

Operating Cash Flow -130.9M
Capital Expenditures -326K
Free Cash Flow -131.23M
FCF Per Share -0.65
Full Cash Flow Statement

Margins

Gross margin is 68.83%, with operating and profit margins of -1423.58% and -1464.61%.

Gross Margin 68.83%
Operating Margin -1423.58%
Pretax Margin -1452.48%
Profit Margin -1464.61%
EBITDA Margin -1078.45%
EBIT Margin -1423.58%
FCF Margin -5132.07%

Dividends & Yields

XFOR does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for XFOR is $3, which is 1478.9% higher than the current price. The consensus rating is "Buy".

Price Target $3
Price Target Difference 1478.9%
Analyst Consensus Buy
Analyst Count 3
Stock Forecasts

Stock Splits

The last stock split was on Mar 14, 2019. It was a backward split with a ratio of 1:6.

Last Split Date Mar 14, 2019
Split Type backward
Split Ratio 1:6

Scores

Altman Z-Score -7.6
Piotroski F-Score 0